Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies

T cells modified via chimeric antigen receptors (CARs) have emerged as a promising treatment modality. Unparalleled clinical efficacy recently demonstrated in refractory B-cell malignancy has brought this new form of adoptive immunotherapy to the center stage. Nonetheless, its current success has al...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Shangjun, Hao, He, Yang, Ge, Zhang, Yi, Fu, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932485/
https://www.ncbi.nlm.nih.gov/pubmed/29850622
http://dx.doi.org/10.1155/2018/2386187
_version_ 1783319826376163328
author Sun, Shangjun
Hao, He
Yang, Ge
Zhang, Yi
Fu, Yang
author_facet Sun, Shangjun
Hao, He
Yang, Ge
Zhang, Yi
Fu, Yang
author_sort Sun, Shangjun
collection PubMed
description T cells modified via chimeric antigen receptors (CARs) have emerged as a promising treatment modality. Unparalleled clinical efficacy recently demonstrated in refractory B-cell malignancy has brought this new form of adoptive immunotherapy to the center stage. Nonetheless, its current success has also highlighted its potential treatment-related toxicities. The adverse events observed in the clinical trials are described in this review, after which, some innovative strategies developed to overcome these unwanted toxicities are outlined, including suicide genes, targeted activation, and other novel strategies.
format Online
Article
Text
id pubmed-5932485
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-59324852018-05-30 Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies Sun, Shangjun Hao, He Yang, Ge Zhang, Yi Fu, Yang J Immunol Res Review Article T cells modified via chimeric antigen receptors (CARs) have emerged as a promising treatment modality. Unparalleled clinical efficacy recently demonstrated in refractory B-cell malignancy has brought this new form of adoptive immunotherapy to the center stage. Nonetheless, its current success has also highlighted its potential treatment-related toxicities. The adverse events observed in the clinical trials are described in this review, after which, some innovative strategies developed to overcome these unwanted toxicities are outlined, including suicide genes, targeted activation, and other novel strategies. Hindawi 2018-04-17 /pmc/articles/PMC5932485/ /pubmed/29850622 http://dx.doi.org/10.1155/2018/2386187 Text en Copyright © 2018 Shangjun Sun et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Sun, Shangjun
Hao, He
Yang, Ge
Zhang, Yi
Fu, Yang
Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
title Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
title_full Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
title_fullStr Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
title_full_unstemmed Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
title_short Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
title_sort immunotherapy with car-modified t cells: toxicities and overcoming strategies
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932485/
https://www.ncbi.nlm.nih.gov/pubmed/29850622
http://dx.doi.org/10.1155/2018/2386187
work_keys_str_mv AT sunshangjun immunotherapywithcarmodifiedtcellstoxicitiesandovercomingstrategies
AT haohe immunotherapywithcarmodifiedtcellstoxicitiesandovercomingstrategies
AT yangge immunotherapywithcarmodifiedtcellstoxicitiesandovercomingstrategies
AT zhangyi immunotherapywithcarmodifiedtcellstoxicitiesandovercomingstrategies
AT fuyang immunotherapywithcarmodifiedtcellstoxicitiesandovercomingstrategies

Ejemplares similares